The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: A review
Abstract
Summary: Valproic acid (VPA; 2‐n‐propylpentanoic acid) is widely used as a major drug in the treatment of epilepsy and in the control of several types of seizures. Being a simple fatty acid, VPA is a substrate for the fatty acid β‐oxidation (FAO) pathway, which takes place primarily in mitochondria. The toxicity of valproate has long been considered to be due primarily to its interference with mitochondrial β‐oxidation. The metabolism of the drug, its effects on enzymes of FAO and their cofactors such as CoA and/or carnitine will be reviewed. The cumulative consequences of VPA therapy in inborn errors of metabolism (IEMs) and the importance of recognizing an underlying IEM in cases of VPA‐induced steatosis and acute liver toxicity are two different concepts that will be emphasized.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mitochondrial dysfunction in Nash: causes, consequences and possible means to prevent it
Begriche, K., Igoudjil, A., Pessayre, D., & Fromenty, B. (2006) · Mitochondrion · doi:10.1016/j.mito.2005.10.004 · Cited by 753
Farkas, V., Bock, I., Cseko, J., & Sandor, A. (1996) · Biochemical Pharmacology · doi:10.1016/s0006-2952(96)00507-2 · Cited by 49
Cited by
Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease
Masarone, M., Rosato, V., Dallio, M., Gravina, A. G., Aglitti, A., Loguercio, C., Federico, A., & Persico, M. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/9547613 · Cited by 648
Foley, K. A., MacFabe, D. F., Vaz, A., Ossenkopp, K., & Kavaliers, M. (2014) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2014.04.001 · Cited by 116
Kim, S. W., Hooker, J. M., Otto, N., Win, K., Muench, L., Shea, C., Carter, P., King, P., Reid, A. E., Volkow, N. D., et al. (2013) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2013.06.007 · Cited by 104
Villaseñor, A., Ramamoorthy, A., Silva dos Santos, M., Lorenzo, M. P., Laje, G., Zarate, C., Barbas, C., & Wainer, I. W. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12494 · Cited by 71
Sex related differences on valproic acid pharmacokinetics after oral single dose
Ibarra, M., Vázquez, M., Fagiolino, P., & Derendorf, H. (2013) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-013-9323-3 · Cited by 63
FKBP51 inhibits GSK3β and augments the effects of distinct psychotropic medications
Gassen, N. C., Hartmann, J., Zannas, A. S., Kretzschmar, A., Zschocke, J., Maccarrone, G., Hafner, K., Zellner, A., Kollmannsberger, L. K., Wagner, K. V., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.38 · Cited by 62
Mechanisms of idiosyncratic drug-induced liver injury
Uetrecht, J. (2019) · Advances in pharmacology · doi:10.1016/bs.apha.2018.12.001 · Cited by 49
Antitumor effect of pharmacologic ascorbate in the B16 murine melanoma model
Serrano, O. K., Parrow, N. L., Violet, P.-C., Yang, J., Zornjak, J., Basseville, A., & Levine, M. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.06.032 · Cited by 29
Guo, K., & van den Beucken, T. (2024) · Cell & Bioscience · doi:10.1186/s13578-024-01317-2 · Cited by 28
Metadata
- Authors
- Silva, M. F. B., Aires, C. C. P., Luis, P. B. M., Ruiter, J. P. N., IJlst, L., Duran, M., Wanders, R. J. A., & Tavares de Almeida, I.
- Venue
- Journal of Inherited Metabolic Disease
- Publisher
- Wiley
- Published
- 2008-04
- Volume
- 31
- Issue
- 2
- Pages
- 205-216
- ISSN
- 0141-8955 (ISSN-L)
- 1573-2665
- OpenAlex
- W2010847506
- Cited by
- 382
- References
- 2
- FWCI
- 9.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
